Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 alone and in combinations for advanced solid tumors
NL-OMON52993Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of feladilimab in Nonhematologic neoplasms (6 arms), sponsored by GSK. Primary endpoints: Adverse events, Dose-limiting toxicities and 5 more. Started Aug 2017; status: completed.
02
Drugs
feladilimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON52993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52993.